About RILP-like protein 1
RILP-like protein 1 (RILPL1) is a protein
from Homo sapiens identified by UniProt accession
Q5EBL4, 403 residues long.
MolForge cross-references it against 0 known binders and
26 disease associations.
Target properties
| Protein name | RILP-like protein 1 |
| UniProt accession | Q5EBL4 |
| Gene | RILPL1 |
| Organism | Homo sapiens |
| Length | 403 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (26)
Diseases linked to this target (Open Targets).
- oculopharyngodistal myopathy · score 0.46
- leukocyte count · score 0.25
- neurodegenerative disease · score 0.25
- triglyceride measurement · score 0.24
- urate measurement · score 0.15
- MODY · score 0.06
- hyperproinsulinemia · score 0.04
- lymphocyte count · score 0.04
- Glycogen storage disease due to hepatic glycogen synthase deficiency · score 0.04
- glycogen storage disorder due to hepatic glycogen synthase deficiency · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5EBL4-F1 | alphafold | PREDICTED | 75.94 | — |
Amino-acid sequence (403 residues)
MEEERGSALA AESALEKNVA ELTVMDVYDI ASLVGHEFER VIDQHGCEAI ARLMPKVVRV LEILEVLVSR HHVAPELDEL RLELDRLRLE RMDRIEKERK HQKELELVED VWRGEAQDLL SQIAQLQEEN KQLMTNLSHK DVNFSEEEFQ KHEGMSERER QVMKKLKEVV DKQRDEIRAK DRELGLKNED VEALQQQQTR LMKINHDLRH RVTVVEAQGK ALIEQKVELE ADLQTKEQEM GSLRAELGKL RERLQGEHSQ NGEEEPETEP VGEESISDAE KVAMDLKDPN RPRFTLQELR DVLHERNELK SKVFLLQEEL AYYKSEEMEE ENRIPQPPPI AHPRTSPQPE SGIKRLFSFF SRDKKRLANT QRNVHIQESF GQWANTHRDD GYTEQGQEAL QHL
Explore RILP-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets